Effect of cyclosporine on rubella virus-specific immune responses in chronic progressive multiple sclerosis

Avindra Nath, Jerry S. Wolinsky, Ronald H. Kerman

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Cyclosporine A (CsA) has been used in putative autoimmune diseases after sensitization to unknown antigens. We have previously shown that CsA prevented continued activation of T-cells in chronic progressive multiple sclerosis (CPMS) patients. The current study was undertaken to determine whether CsA, CsA and prednisone (CsA + P) could suppress immune responses to a common recall antigen. Serum antibody levels were higher in all CPMS patients than age-matched normal controls. However, rubella antibody titers in the CsA or CsA + P groups were no different from a placebo-treated CPMS patient group. The lymphocyte responses to inactivated rubella virus of CsA and CsA + P-treated CPMS patients were lower than placebo and control but not statistically different. Therapy with bot CSA and CSA + P was associated with significantly lower panel mixed leukocyte responses and Ta1 expression than in the placebo-treated group; CD3, CD4, CD8 antigen expression and active rosette formation by T-cells were similar for the three CPMS groups. These results suggest that while CsA exerts measurable effects on non-specific indicators of cellular immunity in CPMS patients, it may not be as effective in suppressing pre-existent specific immune responses.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalJournal of Neuroimmunology
Issue number2
StatePublished - Apr 1989


  • Ciclosporin A
  • Immunity
  • Multiple sclerosis
  • Rubella virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Effect of cyclosporine on rubella virus-specific immune responses in chronic progressive multiple sclerosis'. Together they form a unique fingerprint.

Cite this